Oxybutynin and Clonidine: Older Hot-Flash Options

What are oxybutynin and clonidine?

Oxybutynin and clonidine are prescription medicines first approved for other conditions that clinicians have used off-label to quiet hot flashes and night sweats 1Ref 1The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.The 2023 NAMS nonhormone position statement recommends oxybutynin among nonhormone options for vasomotor symptoms and no longer recommends clonidine because its adverse effects outweigh a modest benefit.. Oxybutynin treats overactive bladder by relaxing bladder muscle, and researchers noticed it also reduces vasomotor symptoms. Clonidine lowers blood pressure by calming nerve signals, and it was tried for hot flashes more than 30 years ago. Neither is a hormone, so both have drawn interest from people who cannot use estrogen or prefer to avoid it 2Ref 2The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Establishes hormone therapy as the most effective treatment for vasomotor symptoms, framing non-hormonal pills as alternatives when hormones are unsuitable or unwanted.. Hormone therapy still relieves hot flashes more completely than either one 2Ref 2The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Establishes hormone therapy as the most effective treatment for vasomotor symptoms, framing non-hormonal pills as alternatives when hormones are unsuitable or unwanted..

Does oxybutynin actually help hot flashes?

Randomized trials show oxybutynin cuts the frequency and severity of hot flashes more than a placebo, and the effect can be meaningful for some women 1Ref 1The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.The 2023 NAMS nonhormone position statement recommends oxybutynin among nonhormone options for vasomotor symptoms and no longer recommends clonidine because its adverse effects outweigh a modest benefit.3Ref 3Grant MD, Marbella A, Wang AT, Pines E, Hoag J, Bonnell C, Ziegler KM, Aronson N (2015).Menopausal Symptoms: Comparative Effectiveness of Therapies (Comparative Effectiveness Review No. 147).AHRQ comparative-effectiveness review supports oxybutynin's benefit over placebo for vasomotor symptoms and provides comparative context across therapies.. The North American Menopause Society added it to its list of recommended nonhormone options in its 2023 statement 1Ref 1The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.The 2023 NAMS nonhormone position statement recommends oxybutynin among nonhormone options for vasomotor symptoms and no longer recommends clonidine because its adverse effects outweigh a modest benefit.. Dry mouth is the most common complaint in trials lasting 8 to 12 weeks, and constipation, blurred vision, or trouble emptying the bladder can also occur. Because medicines with this drying action have been studied for possible long-term effects on memory in older adults, clinicians weigh that when considering extended use 1Ref 1The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.The 2023 NAMS nonhormone position statement recommends oxybutynin among nonhormone options for vasomotor symptoms and no longer recommends clonidine because its adverse effects outweigh a modest benefit.. A 2015 federal evidence review reached broadly similar conclusions about its usefulness 3Ref 3Grant MD, Marbella A, Wang AT, Pines E, Hoag J, Bonnell C, Ziegler KM, Aronson N (2015).Menopausal Symptoms: Comparative Effectiveness of Therapies (Comparative Effectiveness Review No. 147).AHRQ comparative-effectiveness review supports oxybutynin's benefit over placebo for vasomotor symptoms and provides comparative context across therapies..

Why is clonidine no longer recommended?

Clonidine reduces hot flashes only modestly, and its side effects often outweigh that small benefit, which is why the 2023 nonhormone guideline no longer recommends it 1Ref 1The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.The 2023 NAMS nonhormone position statement recommends oxybutynin among nonhormone options for vasomotor symptoms and no longer recommends clonidine because its adverse effects outweigh a modest benefit.. Dry mouth, drowsiness, dizziness, and low blood pressure are common, and stopping it abruptly can make blood pressure rebound sharply. Earlier guidance, including the 2015 position statement, listed clonidine among the options to consider, so some people were prescribed it in the past 4Ref 4The North American Menopause Society (Menopause Society) (2015).Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society.The 2015 NAMS nonhormonal position statement listed clonidine among options to consider, providing the historical contrast to its later downgrade.. That shift is a good example of how menopause care changes as better evidence and newer choices arrive. For most women, other nonhormone medicines now offer a better balance of benefit and tolerability 1Ref 1The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.The 2023 NAMS nonhormone position statement recommends oxybutynin among nonhormone options for vasomotor symptoms and no longer recommends clonidine because its adverse effects outweigh a modest benefit..

How do these fit alongside newer options?

Hormone therapy remains the most effective treatment, so oxybutynin is usually considered when hormones are unsuitable or unwanted 2Ref 2The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Establishes hormone therapy as the most effective treatment for vasomotor symptoms, framing non-hormonal pills as alternatives when hormones are unsuitable or unwanted.. Low-dose antidepressants, gabapentin, and the newer targeted medicine fezolinetant round out the nonhormone menu, each with its own tradeoffs 1Ref 1The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.The 2023 NAMS nonhormone position statement recommends oxybutynin among nonhormone options for vasomotor symptoms and no longer recommends clonidine because its adverse effects outweigh a modest benefit.. Needs also shift across midlife: in perimenopause, when cycles are still irregular, hot flashes may come and go, while after the final period they can settle into a steadier pattern that lasts a median of about 7.4 years, and beyond 10 years for some women 5Ref 5Avis NE, Crawford SL, Greendale G, et al. / Study of Women's Health Across the Nation (SWAN) (2015).Duration of menopausal vasomotor symptoms over the menopause transition.SWAN cohort study documents a median vasomotor-symptom duration of about 7.4 years, extending beyond 10 years for some women..

You can compare these against hormone therapy and read how to handle hot flashes at night.

When nonhormonal hot-flash options need a clinician

A clinician can match the right nonhormone medicine to your symptoms, other conditions, and the medicines you already take. This matters especially if you have low blood pressure, glaucoma, bladder-emptying problems, or take other sedating or drying drugs, since these change which option is safest. A primary care clinician or menopause specialist can also explain how the choices differ in day-to-day use.

As your menopause symptoms and perimenopause symptoms change, the plan is usually revisited. Gale can help you prepare for that conversation.